Form 8-K - Current report:
SEC Accession No. 0001493152-25-026500
Filing Date
2025-12-08
Accepted
2025-12-08 06:15:37
Documents
13
Period of Report
2025-12-07
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 44274
2 EX-99.1 ex99-1.htm EX-99.1 22237
  Complete submission text file 0001493152-25-026500.txt   242234

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE immx-20251207.xsd EX-101.SCH 3014
4 XBRL LABEL FILE immx-20251207_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE immx-20251207_pre.xml EX-101.PRE 22358
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3814
Mailing Address 10573 W. PICO BLVD. #58 LOS ANGELES CA 90064
Business Address 11400 WEST OLYMPIC BLVD. SUITE 200 LOS ANGELES CA 90064 (888) 958-1084
Immix Biopharma, Inc. (Filer) CIK: 0001873835 (see all company filings)

EIN.: 454869378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41159 | Film No.: 251554548
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)